EMD Serono
EMD Serono sponsors 71 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 48 completed. 24 of these trials are in Phase 3-4 (later-stage) and 40 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available, with 1 trials.
Trial Pipeline
71 total, page 2 of 2
RNF and Betaseron® Tolerability Study
NCT00428584
A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies
NCT01080664
AS703569 Phase I in Patients With Solid Tumours
NCT00391521
Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])
NCT00328926
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
NCT00111839
EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide
NCT00132522
Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction
NCT00213148
Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
NCT01077960
Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency
NCT00109733
Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis
NCT00110396
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
NCT00093964
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
NCT00105521
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
NCT00105508
Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis
NCT00090129
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
NCT00082628
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
NCT00078338
A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer
NCT00073541
Rebif® Pregnancy Registry
NCT00338741
Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia
NCT00314288
Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment
NCT00016237
Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients
NCT00262314
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 24 |
| Phase 3 | 17 |
| Phase 4 | 7 |
What the Pipeline for EMD Serono Shows
According to the ClinicalTrials.gov registry, EMD Serono is linked to 71 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting, about 0% of the sponsor's indexed portfolio, and 48 are already marked complete, representing roughly 68% of the total.
The phase mix for EMD Serono reports 24 late-stage studies (Phase 3 and Phase 4 combined) and 40 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for EMD Serono is Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available with 1 linked trial, and 5 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.